Environmental, Social And Governance Report

Overview

The report highlights JW Therapeutics' 2021 transition to commercialization after China's NMPA approved Carteyva®, its anti-CD19 CAR-T product. It reports 534 employees and 100% training coverage, alongside total energy consumption of 9,954.49 MWh and a target to reduce Scope 1 and Scope 2 GHG emissions intensity by 40% by the end of 2025. The report also states that there were no work-related injuries and no work-related fatalities in the past three years.

Document

Report type: Sustainability Report
Class: Dedicated
Scope: Full report
Fiscal year: 2021
Period: 1 January 2021 – 31 December 2021
Language: English
Pages
File size

Reporting standards, commitments and assurance details are available with a free account.

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP
Other

Materiality

Assessment
Basis
Matrix

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services